LENZ Therapeutics to Host Expert Panel on June 18, 2024

SAN DIEGO, June 10, 2024 — LENZ Therapeutics, Inc., a biopharmaceutical company advancing the first aceclidine-based eye drop to enhance near vision for individuals with presbyopia, has announced an upcoming Key Opinion Leader (KOL) event. The event is scheduled for Tuesday, June 18, 2024, at 8:00 a.m. ET and will showcase insights from Key Opinion Leaders and Principal Investigators on presbyopia treatment options and the Phase 3 CLARITY study data for their product candidate, LNZ100.

Key speakers at the event will include Eef Schimmelpennink, Chief Executive Officer of LENZ Therapeutics, and Marc Odrich, M.D., Chief Medical Officer. Guest speakers will present their findings and perspectives on presbyopia and LNZ100. They include:

- Jason Bacharach, M.D.: Founding Partner and Medical & Research Director at North Bay Eye Associates, Inc. Dr. Bacharach has been a primary investigator in over 200 clinical trials across phases I through IV in ophthalmology. He has served as the Chair of the American Academy’s Ophthalmic Knowledge Based Panel for Glaucoma and is a board examiner for the American Board of Ophthalmology. He has received the Achievement Award (2005) and Secretariat Award (2013) from the American Academy of Ophthalmology. Dr. Bacharach was a Principal Investigator in the CLARITY Phase 3 study.

- Marc Bloomenstein, O.D.: Director of Optometric Services at the Schwartz Laser Eye Center in Scottsdale, Arizona. Dr. Bloomenstein is the Chair of the Education Committee for Vision Expo, AOA CE Committee, and has served on the board of the Ocular Surface Society of Optometry (OSSO). He is also a founding member of the Optometric Cornea, Cataract, and Refractive Society (OCCRS). Dr. Bloomenstein was a Principal Investigator in the CLARITY Phase 3 study.

- Milton Hom, O.D.: An internationally recognized expert in therapeutics, dry eye, presbyopia, and contact lenses. Dr. Hom is co-medical director of the multi-site Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA) study, and has authored four books along with over 200 papers and peer-reviewed abstracts. Dr. Hom served as a Principal Investigator in the CLARITY Phase 3 study.

The session will include a live question-and-answer segment and attendees can join via a live webcast. Participants interested in joining virtually can pre-register for the webcast through the link provided on the LENZ Therapeutics website. Supporting presentation materials will be available in the Events section of the Investor Relations page of the LENZ Therapeutics website during the live event. An archived replay of the webcast will also be available for those unable to attend.

About LENZ Therapeutics:

LENZ Therapeutics is a late-stage clinical biopharmaceutical company headquartered in San Diego, California. The company is dedicated to developing and commercializing LNZ100, an aceclidine-based eye drop designed to improve near vision for people with presbyopia. LNZ100 is a preservative-free, single-use, once-daily solution that has been evaluated in a Phase 3 CLARITY study as a potential treatment for presbyopia, a condition affecting approximately 1.8 billion people globally and 128 million in the United States. LENZ Therapeutics is committed to providing a pharmaceutical solution that enhances vision for individuals with presbyopia.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!